Growth Acceleration Expected in Second Half with Added New Drug Momentum

[Click e-Stock] Celltrion: Strong Q2 Surprise Earnings and New Drug Momentum View original image

On July 7, Hyundai Motor Securities maintained its "BUY" investment rating and target price of 270,000 won for Celltrion, stating that the company delivered a surprise earnings result in the second quarter due to faster-than-expected growth in its new product lineup. The brokerage firm added that further growth in earnings will become more pronounced in the second half of the year, driven by U.S. launches and new drug momentum.


The firm explained that Celltrion's consolidated sales for the second quarter reached 1.3 trillion won, up 35% year-on-year, while operating profit soared 77% to 430 billion won. It noted that both sales and operating profit exceeded market consensus for the second consecutive quarter, following strong results in the first quarter.


Hyunseok Kim, a researcher at Hyundai Motor Securities, commented, "Sales of the new product lineup are growing much faster than expected." He added, "In particular, Zymfentra continues to break its record for the highest prescription figures, and sales of Omlyclo, a Xolair biosimilar that currently faces no competition, are believed to have increased significantly."


The market had initially expected Celltrion's earnings growth to accelerate from the second half of this year, largely due to the base effect from the mass launch of new products in the second half of 2025. However, Kim emphasized that the company has already demonstrated faster-than-expected growth from the second quarter, boosting expectations for the second half. He noted that key new products such as Stekyma, Idenzelt, and Omlyclo are set to launch in the U.S. market in succession in the second half, which is expected to drive both top-line growth and improved profitability.


Not only is the biosimilar business performing well, but tangible results are also emerging from the new drug development segment. Celltrion is preparing to release phase 1 clinical results for its in-house developed c-MET-targeted ADC (antibody-drug conjugate) therapy "CT-P70" and Nectin-4-targeted ADC "CT-P71" in the second half of this year.



New drug development through global partnerships is also progressing smoothly. "CT-P77," an FcRn-targeted autoimmune disease therapy co-developed with Kyowa Kirin, aims to submit an Investigational New Drug (IND) application this year, while the company is developing a triple fusion protein anti-cancer pipeline with Must Bio. In addition, Celltrion is actively collaborating with AI technology companies such as Portrait and Galux to discover new antibodies and target proteins.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing